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Accepted 12 November 2015Rituximab, amonoclonal B-cell cytolytic antibody, has beneﬁcial effects in patients with inﬂammatory demyelin-
ating diseases. So far, little data exists on B-cell subset recovery after rituximab treatment in inﬂammatory demy-
elinating diseases of the central nervous system (CNS). To elucidate whether rituximab promotes qualitative
changes in the IgG memory B-cell repertoire we performed a single cell analysis in three patients with CNS de-
myelination. We did not observe any qualitative changes but detected an increased clonal expansion in the IgG
memory B-cell compartment after treatment, indicating that a single course of rituximab does not eliminate spe-
ciﬁc IgG memory B-cells.







Rituximab is a B-cell cytolytic chimeric IgG1 monoclonal antibody
that targets the CD20 molecule, expressed on pre-B and mature B-
cells, until their differentiation into plasma cells. Rituximab causes B-
cell depletion by antibody-dependent cell-mediated cytotoxicity
(ADCC), complement-mediated lysis and induction of apoptosis. Mainly
peripheral B-cells are affected, whereas germinal-center B-cells and, in
particular, marginal-zone B-cells were found to be resistant to killing
(Edwards and Cambridge, 2006; Gong et al., 2005).
Rituximab has already been proven to have beneﬁcial effects in pa-
tients with inﬂammatory demyelinating disorders (Bar-Or et al., 2008;
Cree et al., 2005; Dalakas et al., 2009; Hauser et al., 2008; Kim et al.,
2013; Kim et al., 2011; Monson et al., 2005), but so far little data exists
on B cell subset recovery after rituximab treatment in inﬂammatory de-
myelinating diseases of the central nervous system (CNS).We previous-
ly reported that the therapeutic effect of rituximab in anti-myelin
associated glycoprotein (MAG) neuropathy depends on efﬁcient deple-
tion of non-circulating B-cells and reconﬁguration of the B-cell memory
compartment (Maurer et al., 2012). In this study we could demonstratenn), markus.reindl@i-med.ac.at
. This is an open access article underthat the long-term immunomodulatory effects of rituximab in anti-
MAG neuropathy are mediated by the sustained reduction of expanded
autoreactive IgMmemory B-cells. Patients who responded to rituximab
showed a reduction in the clonal expanded IgM memory B-cell com-
partment after therapy, which was associated with clinical disease re-
mission. Interestingly, the frequency of clonal expanded IgG memory
B-cells slightly increased after rituximab therapy. To prove whether
this ﬁnding is unique to the anti-MAG-neuropathy patients, we addi-
tionally examined the peripheral IgG gene repertoire in patients with
inﬂammatory demyelinating disorders of the CNS during rituximab
therapy. We have analyzed one patient with aquaporin-4 (AQP4) anti-
body positive neuromyelitis optica (NMO), one patient with AQP4-
antibody negative recurrent transverse myelitis and one patient with
primary progressive multiple sclerosis (PPMS).
2. Materials and methods
2.1. Patients
The studywas approved by the institutional review board ofMedical
University of Innsbruck (study no. UN3041 257/4.8) and all participants
gave written informed consent. One patient with NMO (patient 1), one
patient with recurrent myelitis (patient 2) and one patient with PPMS
(patient 3) were included in this observational study (Table 1). Patients
were treatedwith rituximab at a dosage of 375mg/m2 and 100–250mg
prednisolone was administered i.v. prior to each rituximab application.
Patient 1 and patient 2 were recruited from a recently published studythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographical, clinical and immunological characteristics of patients.
Patient 1 Patient 2 Patient 3
Gender Female Male Female
Age (Years) 20 21 46
Diagnosis Neuromyelitis optica Recurrent myelitis Primary progressive multiple sclerosis
Disease duration before therapy (years) 4.3 0.6 5.0
Time from ﬁrst to second sample (months) 5 7 9
Percentage of total B-cells before therapy 6.8 10.0 12.4
Percentage of IgG memory B cells before therapy 0.80 0.90 1.60
Percentage of total B-cells after therapy 0.7 2.0 0.6
Percentage of IgG memory B cells after therapy 0.05 0.10 0.05
AQP4-antibody titer before therapy 1:20,480 0 0
AQP4-antibody titer after therapy 1:20,480 0 0
Serum BAFF ng/ml before therapy 0.64 0.5 0.58
Serum BAFF ng/ml after therapy 3.45 5.11 2.55
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(NMOSD) from Medical University of Innsbruck (Gredler et al., 2013).
Serum AQP4-antibody and B-cell activating factor (BAFF) levels were
measured as previously described (Gredler et al., 2013; Mader et al.,
2010).
2.2. Flow cytometry and single cell analysis
Single cell analysiswas performed the sameway as for the anti-MAG
neuropathy patients as previously described (Maurer et al., 2012). In
brief, frozen peripheral blood mononuclear cells (PBMC) were thawed
in FACS buffer (2 mM EDTA, 5% FCS, 20 μg/ml DNAse [Roche] in PBS).
After thawing, the PBMCs were strained (0.22 μm cell strainer; BD)
and centrifuged for 15 min at 150 g and 4 °C. The cells were incubated
with PE-conjugated anti-CD27 clone M-T271, PE-Cy7-conjugated anti-
CD19 clone SJ25C1, biotin-conjugated anti-IgG clone G18-145, and
FITC-conjugated streptavidin (all BD) and with component H
(Invitrogen) for dead cell discrimination. Single CD19+ CD27+ IgG+
memory B-cells were puriﬁed by ﬂow cytometric cell sorting using a
Facs Aria cell sorter and Diva software (both BD). Single cell sorting
was directly into a 96-well plate (thermoquick PCR-Plate; Greiner
bioOne) with 20 μl OneStep RT-PCR reactionmix (Qiagen) supplement-
ed with 0.5 μM each of Igh variable region-speciﬁc forward and IgG re-
verse primers per well (Tiller et al., 2008). Directly after sorting plates
were incubated for 60 min at 50 °C for reverse transcription. After the
reverse transcription step, DNApolymerasewas activatedwith an initial
step of 15 min at 95 °C. Ampliﬁcation of the resulting cDNA of Igh was
performed at an annealing temperature of 58 °C for 45 s, an elongation
temperature of 72 °C for 1min, and a denaturation temperature of 94 °C
for 30 s for 48 cycles. Nontemplate controls were included to exclude
any contaminations in the master mix.
To reduce PCR error rates, we used the HotStar Taq DNA polymerase
(Qiagen) with an error rate of 2 × 10−5 per nucleotide and cycle. PCR
amplicons were separated by electrophoresis on a 1.2% agarose gel. To
avoid cross contaminations on the gel, PCR products were physically
separated from each other. Bandswith the correctmass (approximately
500 bp)were excised using individual sterile scalpels; DNAwas extract-
ed (QiagenMiniElute Gel Extraction Kit) and sequenced. The sequenced
variable region of the ampliﬁed Ighwas corrected with CLCMainWork-
bench and analyzed on the international immunogenetic information
system (Brochet et al., 2008; Giudicelli et al., 2011). The variable region
was analyzed for VH, DH, and JH usage; somatic hypermutations
(SHM); CDR3 length; pI; and clonal expansion.
2.3. Sequence analysis
Clonal expansions were determined by similar CDR3 amino acid se-
quences and VH, DH, and JH usage in the IgG memory B-cell pool. The
length of the CDR3 was deﬁned as the number of amino acids from
the third position after the cysteine motive of the CDR3 to thetryptophan amino acid. For pI analysis, we used the entire amino acid
sequence of the CDR3 and calculated it with the tool on ExPASy proteo-
mics server (Gasteiger et al., 2003). The VH, DH, and JH gene usage was
weight balanced by the number of sequences derived from each donor
to avoid tempering the result by different amount of sequences due to
clonal expansion or PCR efﬁcacy. For the SHM analysis, sequences
were ﬁrst blasted against the germline sequences in the database of
IMGT.2.4. Statistical analysis
The two-tailed Fisher exact test was used to compare frequencies of
VH, DH and JH gene family usage and the size of clonal expansions. All
analyses are based on individual sequences, and data in ﬁgures, in
which error bars are shown, are presented asmean±SEM. Sincewe an-
alyzed pooled sequence data, a repeated-observation analysis was not
applied. A P value less than 0.05 was considered signiﬁcant.3. Results
3.1. No qualitative changes in the IgG gene repertoire after rituximab
infusion
To determine whether rituximab induces qualitative changes in the
peripheral IgG memory B-cell repertoire, we ampliﬁed and sequenced
Ig heavy chain (Igh) genes of single sorted IgG memory B-cells
(CD19+ CD27+ IgG+) before and 4–9 months after therapy (Table 1).
The percentage of the B-cell and the IgG memory B-cell pool within
the peripheral lymphocyte compartment declined dramatically after ri-
tuximab therapy (Table 1). Nevertheless, we could sort sufﬁcient B-cells
for single cell analysis after therapy. Sequence analysis revealed no
major differences in the VH, DH and JH gene family usage between the
patients (Fig. 1). Additionally, we could not ﬁnd differences in the
gene family usage of our patient cohort and the anti-MAG neuropathy
patients and demographically matched healthy blood donors (Maurer
et al., 2012). Furthermore, we could not ﬁnd any signiﬁcant differences
in VH, DH and JH gene usage before and after rituximab therapy (Fig. 1
and Supplementary Table). Next, we examined heavy chain characteris-
tics of the complementary-determining region 3 (CDR3), as long and
positively charged CDR3 regions have been associated with antibody-
mediated autoreactivity (Wardemann et al., 2003; Yurasov et al.,
2005). Again, we could not detect signiﬁcant differences in length and
isoelectric point (PI) after rituximab therapy in our patients. These
data are compatible with our previously reported ﬁndings in
rituximab-treated patients with anti-MAG neuropathy, at least for the
IgG memory compartment (Maurer et al., 2012). We conclude that ri-
tuximab does not promote qualitative changes in the IgGmemory com-
partment in patients with inﬂammatory demyelination.
Fig. 1. IgG gene repertoire analysis in patients with NMO (patient 1), myelitis (patient 2) and MS (patient 3) and all patients before and 5–9 months after rituximab treatment. Igh gene
variable (V) region, diversity (D) region and joining (J) region repertoires in single cell-sorted IgGmemory B-cells (CD19+CD27+ IgG+)were analyzed. Clonally expanded sequenceswere
counted as one sequence. Numbers within circles indicate the number of individual sequences analyzed per patient and time point. The 2-tailed Fisher exact test was used to evaluate VH,
DH, and JH repertoire.
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Interestingly, the frequencies of clonally expanded IgG memory B-
cells signiﬁcantly changed in the three patients analyzed in this study
before and after rituximab therapy. An increased IgGmemory B-cell ex-
pansion was observed in all patients after rituximab therapy suggesting
clonal expansion of non-depleted IgGmemory B-cells, but not necessar-
ily autoreactive ones (Fig. 2 and Supplementary Table).We could detectFig. 2. Frequency of clonally expanded IgGmemory B-cells patientswith NMO(patient 1),myeli
berswithin circles indicate the number of individual sequences analyzed per patient before and
expanded sequences (dark gray pie area). This was calculated as a total number of expanded se
example in the case of patient three one sequence was found two times before rituximab treatm
found in 115 sequences.signiﬁcantly more IgG memory B-cell expansions after therapy in all
three patients (P b 0.0001), suggesting that the IgG memory B-cell
pool was less efﬁciently depleted than the naïve B-cell compartment.
3.3. Increased serum BAFF levels after rituximab treatment
Additionally, we compared AQP4-antibody and serum BAFF levels
shortly after treatment and during further follow-up and repeatedtis (patient 2),MS (patient 3) and all patients 5–9months after rituximab treatment. Num-
after rituximab therapy. The frequency is represented as percentage of the total number of
quences including different expansions divided by the total number of the sequences. For
ent of a total of 148 sequences and after treatment a total of 17 expanded sequenceswere
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treatment with rituximab reduces AQP4-antibody levels and leads to
an increase of serum BAFF levels (Gredler et al., 2013; Kim et al., 2013;
Pellkofer et al., 2011). Antibody levels did not decline shortly after the
ﬁrst rituximab administration in our seropositive NMO case (patient
1), but we could observe a reduction in AQP4-IgG levels after long-
term treatment as serum titer decreased from 1:20,480 to 1:640 after
1 year and to 1:160 after 3.5 years of repeated rituximab treatment.
Serum BAFF levels dramatically increased after the initial treatment
and stayed high during follow-up observations (Table 1).
4. Discussion
Our study demonstrates that a single course of rituximab does not
promote any qualitative changes of the IgG memory B-cell repertoire
but causes increased clonal expansion of IgG memory B-cells as well
as increased serumBAFF levels. The effect of rituximab on the IgMmem-
ory B-cell repertoire in patients with IgM anti-MAG demyelinating neu-
ropathy has already been investigated (Maurer et al., 2012). In
accordance with this study, we report here the effect of rituximab on
the peripheral IgG memory B-cell repertoire in patients with CNS auto-
immunity, inwhich autoantibodies of the IgG class aremore likely to af-
fect the pathogenesis. The repopulated IgG clones do not show
signiﬁcant alterations in their VH, DH and JH segment usage proﬁles.
This was already demonstrated in the clonal expanded IgM repertoire
of the anti-MAG patients. Repopulation and clonal expansion of the
IgGmemory compartment shortly after treatment contrasts with a pre-
vious study on depletion of panel reactive alloantibodies in which the
naïve but not the IgG memory B-cells repopulate (Sidner et al., 2004).
Similar results were recently obtained by Quan and colleagues who de-
termined that after rituximab induced B-cell depletion, repopulation
was characterized by the predominance of regulatory B-cells (Breg)
rather than memory B-cells. Those Breg subsets are suspected to play
a protective role in autoimmune diseases through production of
Interleukin-10 (Quan et al., 2015). However, Leandro and colleagues
could alsoﬁndhigher numbers of IgGmemory B-cells in rheumatoid ar-
thritis patients who relapsed on return of B-cells (Leandro et al., 2006).
We conclude that a single dose of rituximab may not deplete the IgG
memory B-cells efﬁciently, as the compartment expands shortly after
administration. Whether the expanded IgG memory B-cells are
autoreactive is still unknown sincewe did not test their antibodies reac-
tivity. Nevertheless, we speculate that at least a few autoreactive cells
could still survive, undergo clonal expansion and turn into short-lived
antibody secreting plasma cells as serumantibody levels did not decline
in our AQP4-antibody positive NMO patient after the initial rituximab
infusion. Further investigation on single cell analysis in long-term treat-
ed patients could provewhether additional courses of rituximab lead to
sufﬁcient depletion of autoreactive IgGmemory B-cells andwill contrib-
ute to a better understanding on the impact of rituximab on peripheral
IgG memory B-cells in autoimmune disorders. Moreover, it would be
very important to see whether rituximab also affects the cerebrospinal
ﬂuid (CSF) B-cell pool because recent studies have indicated that the pe-
ripheral and CSF B-cell pools are only partly overlapping (Kowarik et al.,
2015; Obermeier et al., 2008) and therefore it is unclear whether the
phenomenon observed in our study might also occur in the CSF B-cell
pool. Unfortunately this was not possible in our study because of the
lack of CSF samples due to ethical reasons.
We could not observe an increase of AQP4-antibodies in our sero-
positive NMOpatient after repopulation and expansion of the IgGmem-
ory B-cell compartment, which suggests that these cells are either not
autoreactive, or they did not turn into antibody secreting plasma cells.
On the contrary, we could observe a reduction of serum AQP4-
antibodies after repeated rituximab infusion, suggesting that not only
autoreactive B-cells, but also their corresponding plasma cells are, at
least indirectly, affected. Previous studies on the long-term effect of ri-
tuximab on antibody titers of anamnestic antigens, such as tetanustoxoid, revealed that those titers remain stable, suggesting that rituxi-
mab has a different effect on autoreactivememory B-cells and their cor-
responding short-lived plasma cells, compared to certain anamnestic
memory B-cells and their corresponding long-lived plasma cells,
which are responsible for post-vaccination responses (Dalakas, 2008).
We further observed an increase in serum BAFF levels shortly after
theﬁrst rituximab infusion. BAFF, a cytokine of the tumor necrosis factor
family (TNF), is necessary for B-cell differentiation and survival. BAFF
and it's corresponding TNF receptors were already proven to predispose
to autoimmunity in experimental animal models (Gross et al., 2000;
Mackay et al., 1999; Thompson et al., 2001). In human studies, levels
of BAFF in the blood strongly increase during B-cell depletion and de-
crease when B-cells return (Edwards and Cambridge, 2006). Further-
more, increased serum BAFF levels were already associated with a
higher risk of relapses shortly after treatment (Nakashima et al., 2011;
Perumal et al., 2015). Interestingly, we could also observe a single re-
lapse in our seropositive NMO case (patient 1) one month after the ini-
tial rituximab treatment that can be associated with increased serum
BAFF levels. One possible explanation for this relapse might be that
due to insufﬁcient depletion, remaining B-cells undergo a fast clonal ex-
pansion upon increased BAFF signaling. Alternatively, reactivation of
autoreactive long-lived plasma cells, which are not targeted by rituxi-
mab, leads to reactivation of disease. This observation is consistent
with other reports on an increase in disease activity shortly after ritux-
imab treatment (Nakashima et al., 2011; Perumal et al., 2015).
Our study has the following limitations: 1) the number of included
patients is low and the three patients had different autoimmune demy-
elinating disorders. This selection was based on a recently published
study on the effect of rituximab on patients with NMOSD (Gredler
et al., 2013). We are aware that this heterogeneity might complicate in-
terpretation of the results because they could be inﬂuenced by the un-
derlying disorders. However, the larger number of patients with MS or
NMOSD which have been treated with rituximab in clinical and case
studies revealed a comparable beneﬁcial effect of rituximab in these dis-
orders (Bar-Or et al., 2008; Cree et al., 2005; Dalakas et al., 2009; Hauser
et al., 2008; Kim et al., 2013; Kim et al., 2011; Monson et al., 2005). Fur-
ther, our ﬁndings of increased clonal expansion of IgG memory B-cells
are comparable with ﬁndings already reported in anti-MAG neuropathy
patients (Maurer et al., 2012). In the anti-MAG study we analyzed the
IgG memory compartment of 19 rituximab treated patients. The anti-
MAG neuropathy patients showed a similar picture of the IgG memory
compartment in regard to clonal expansions, VH and SHM as the three
patients examined in this study (Maurer et al., 2012). Thereforewe con-
clude that the three heterogeneous patients in this report show similar
response to rituximab therapy as the 19 published patients with anti-
MAG neuropathy. 2) Since the percentage of the IgG memory B-cells is
very low after therapy (b2%) it is very likely that we ﬁnd a sequence
more then once. For an example if there is a small infection thememory
B cell expands and newly formed IgG memory B-cell are less diluted in
the total pool of B-cells. 3) The numbers of single memory B cells ana-
lyzed for VDL-segment usage was limited (up to 150 cells per patient)
and thus it could be argued that they might not be representative of
the IgG memory B cell compartment. However, similar numbers have
been used in previous comparable studies (Amara et al., 2013;
Benckert et al., 2011; Owens et al., 2007; Scheid et al., 2009; Tiller
et al., 2007; Yurasov et al., 2006).
In conclusion, B-cell reconstitution following rituximab therapy is
associated with clonal expansion of the IgG memory B-cell compart-
ment but not with qualitative changes in the B-cell repertoire in the pa-
tients analyzed in this study. However, during long-term treatment
AQP4-IgG serum levels decline, whereas serum BAFF levels remain
high. Treatment with rituximab is a promising approach for immuno-
therapy of neurological diseases but as there is different contribution
of B-cells in autoimmune disorders, and the degree of clinical response
varies from patient to patient, further studies on autoreactive B-cells
and their corresponding antibodies need to be performed.
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